Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to Salix: Salix alba, Slackware
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for Salix

References in periodicals archive ?
On 16 March, Valeant agreed to increase its offer for Salix in the face of a competing bid from Irish drugmaker Endo Pharmaceuticals.
Valeant has raised its bid to acquire all the outstanding common stock of Salix from USD 158.
Following the proposed merger agreement between Salix and Cosmo Pharmaceuticals S.
Valeant said that its deal delivers "immediate and certain value" to Salix shareholders.
Despite the announcement of crofelemer's highly statistically significant Phase 3 ADVENT trial results for CRO-HIV on November 4, 2010, Salix did not file the NDA with the FDA for this indication until December 2011 - after Napo filed suit against Salix and served Salix with its notice of termination of the Collaboration Agreement.
11 March 2015 - Canadian drugmaker Valeant Pharmaceuticals International Inc will raise its offer for US-based Salix Pharmaceuticals Ltd.
The parties decided to terminate the agreement because the changed political environment had created more uncertainty regarding the potential benefits of the merger, Salix president and CEO Carolyn Logan explained.
11 March 2015 - US-based drugmaker Salix Pharmaceuticals, Ltd.
As a result of the all-stock deal, Salix will become a fully-controlled unit of Cosmo Pharmaceuticals' Irish subsidiary Cosmo Technologies Ltd, which will be renamed Salix Pharmaceuticals Plc.
9 July 2014 - US Salix Pharmaceuticals Ltd (NASDAQ:SLXP) has inked a final accord to merge with an Irish subsidiary of Italian Cosmo Pharmaceuticals SpA (SWX:COPN), the pair said.
Napo") announced a legal victory today in a dispute with Salix Pharmaceuticals, Inc.
Salix Pharmaceuticals Ltd (Nasdaq:SLXP) has acquired rights to Lumacan from Photocure (OSE: PHO.
The Salix Twitter account and Facebook page will serve as building blocks as the Company establishes a foundation in social media.
The notes will be senior unsecured obligations of Salix and interest will be payable semi-annually at a rate of 2.
In connection with this offering, Salix plans to enter into capped call transactions with one or more underwriters in the offering or their respective affiliates.